Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial

Joanna M. Zakrzewska(Institute of Cardiology), Simon Tate(Ricardo Prague (Czechia)), Dominique Derjean, Lars Bendtsen(University of Copenhagen), Kevin P. Gunn, Dominik A. Ettlin, Mark Obermann(University of Duisburg-Essen), Gary Layton(University of Geneva), G. Cruccu(Apple (Israel)), Valérie Morisset, Joanne Palmer, Mark Estación(Yale University), Gerard M.P. Giblin, Stephen G. Waxman(Yale University)
The Lancet Neurology
February 17, 2017
Cited by 201


Related Papers